MX2015000683A - Metodo para producir moleculas monomericas y multimericas y uso de las mismas. - Google Patents
Metodo para producir moleculas monomericas y multimericas y uso de las mismas.Info
- Publication number
- MX2015000683A MX2015000683A MX2015000683A MX2015000683A MX2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- denotes
- mer
- region
- biologically active
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 230000004927 fusion Effects 0.000 abstract 3
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Aquí se reporta un método para la producción de un polipéptido que es activo biológicamente como n-mer que comprende un ácido nucléico que codifica un polipéptido de fusión de acuerdo con la siguiente fórmula (Bn-CS0-Is-CSp-FC-CSq-It-CSr-Bm)u, en donde B denota un polipéptido que es biológicamente activo como n-mer y forma agregados/multímeros no definidos durante la expresión en la ausencia de una región de Fc fusionada, FC denota un polipéptido de la región de Fc de cadena pesada, CS denota un sitio de escisión, e I denota una secuencia de aminoácidos de intervención, en donde FC no se aglutina substancialmente a un receptor de Fc, recuperar el polipéptido de fusión de la célula o del medio de cultivo, escindiendo opcionalmente el polipéptido de fusión con una proteasa, y producir por esto un polipéptido que es biológicamente activo como n-mer y forma agregados/multímeros no definidos durante la expresión en la ausencia de una región de Fc fusionada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12179021 | 2012-08-02 | ||
PCT/EP2013/066096 WO2014020069A1 (en) | 2012-08-02 | 2013-07-31 | Method for producing monomeric and multimeric molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015000683A true MX2015000683A (es) | 2015-04-10 |
Family
ID=48914281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015000683A MX2015000683A (es) | 2012-08-02 | 2013-07-31 | Metodo para producir moleculas monomericas y multimericas y uso de las mismas. |
Country Status (13)
Country | Link |
---|---|
US (3) | US20150218250A1 (es) |
EP (1) | EP2880169B1 (es) |
JP (1) | JP6388581B2 (es) |
KR (1) | KR20150037959A (es) |
CN (1) | CN104508133B (es) |
BR (1) | BR112015002091A2 (es) |
CA (1) | CA2876099A1 (es) |
ES (1) | ES2633894T3 (es) |
HK (1) | HK1208880A1 (es) |
MX (1) | MX2015000683A (es) |
RU (1) | RU2015106812A (es) |
SG (1) | SG11201408530YA (es) |
WO (1) | WO2014020069A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015226100B2 (en) | 2014-03-05 | 2020-05-07 | UCB Biopharma SRL | Multimeric Fc proteins |
WO2016010014A1 (ja) | 2014-07-15 | 2016-01-21 | アステラス製薬株式会社 | 新規抗ヒトTie2抗体 |
RU2713131C1 (ru) * | 2014-11-06 | 2020-02-03 | Ф. Хоффманн-Ля Рош Аг | ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
CN109311948B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 清洁和/或消毒分离基质的方法 |
JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
EP3492166A4 (en) * | 2016-08-01 | 2020-03-11 | Kaneka Corporation | ADSORPTION AGENT FOR CALCIPROTE PARTICLES, ADSORPTION REMOVAL SYSTEM AND METHOD FOR USE THEREOF |
CA3033475A1 (en) | 2016-08-10 | 2018-02-15 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
CN116970060A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
JP7356726B2 (ja) * | 2017-09-25 | 2023-10-05 | ディンフー バイオターゲット カンパニー リミテッド | タンパク性ヘテロ二量体及びその使用 |
MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
PE20211279A1 (es) | 2018-10-23 | 2021-07-19 | Dragonfly Therapeutics Inc | Proteinas heterodimericas fusionadas con fc |
KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
CN116348481A (zh) * | 2020-08-19 | 2023-06-27 | 詹森生物科技公司 | 使用工程化配体的材料和方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4105480A1 (de) * | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
US6284236B1 (en) * | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
BR9908226A (pt) * | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
EP1098666B1 (en) | 1998-07-17 | 2013-01-16 | The United States of America, represented by the Secretary, Department of Health and Human Services | Water-soluble drugs and methods for their production |
JP2002534962A (ja) * | 1999-01-07 | 2002-10-22 | レキシジェン ファーマシューティカルズ コーポレイション | Fc融合タンパク質としての抗肥満症タンパク質の発現および輸送 |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
NZ517184A (en) * | 1999-07-13 | 2004-02-27 | Bolder Biotechnology Inc | Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain |
EP1252192B1 (en) * | 2000-02-11 | 2006-08-16 | MERCK PATENT GmbH | Enhancing the circulating half-life of antibody-based fusion proteins |
SK10472003A3 (sk) | 2001-02-23 | 2004-03-02 | Immunex Corporation | Zvýšený výťažok aktívnych proteínov |
AU2002333502A1 (en) * | 2002-02-10 | 2003-09-04 | Apoxis Sa | Fusion constructs containing active sections of tnf ligands |
US20080131431A1 (en) | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
AT505262A1 (de) | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
WO2010048313A2 (en) | 2008-10-22 | 2010-04-29 | Biogen Idec Ma Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
EP2184070A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
EP3590965A1 (en) * | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
WO2012146630A1 (en) * | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
-
2013
- 2013-07-31 SG SG11201408530YA patent/SG11201408530YA/en unknown
- 2013-07-31 CN CN201380040175.9A patent/CN104508133B/zh active Active
- 2013-07-31 KR KR1020157002700A patent/KR20150037959A/ko not_active Application Discontinuation
- 2013-07-31 JP JP2015524776A patent/JP6388581B2/ja active Active
- 2013-07-31 MX MX2015000683A patent/MX2015000683A/es unknown
- 2013-07-31 RU RU2015106812A patent/RU2015106812A/ru not_active Application Discontinuation
- 2013-07-31 EP EP13744530.0A patent/EP2880169B1/en active Active
- 2013-07-31 CA CA2876099A patent/CA2876099A1/en not_active Abandoned
- 2013-07-31 BR BR112015002091A patent/BR112015002091A2/pt not_active IP Right Cessation
- 2013-07-31 WO PCT/EP2013/066096 patent/WO2014020069A1/en active Application Filing
- 2013-07-31 ES ES13744530.0T patent/ES2633894T3/es active Active
-
2015
- 2015-02-02 US US14/611,566 patent/US20150218250A1/en not_active Abandoned
- 2015-09-29 HK HK15109566.8A patent/HK1208880A1/xx unknown
-
2017
- 2017-05-09 US US15/590,374 patent/US10570188B2/en active Active
-
2020
- 2020-01-30 US US16/777,138 patent/US11254728B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170342128A1 (en) | 2017-11-30 |
US20150218250A1 (en) | 2015-08-06 |
US20200157183A1 (en) | 2020-05-21 |
ES2633894T3 (es) | 2017-09-25 |
CA2876099A1 (en) | 2014-02-06 |
US11254728B2 (en) | 2022-02-22 |
WO2014020069A1 (en) | 2014-02-06 |
EP2880169B1 (en) | 2017-05-17 |
US10570188B2 (en) | 2020-02-25 |
JP6388581B2 (ja) | 2018-09-12 |
BR112015002091A2 (pt) | 2017-12-12 |
CN104508133A (zh) | 2015-04-08 |
RU2015106812A (ru) | 2016-09-27 |
EP2880169A1 (en) | 2015-06-10 |
JP2015531591A (ja) | 2015-11-05 |
CN104508133B (zh) | 2018-04-20 |
HK1208880A1 (en) | 2016-03-18 |
KR20150037959A (ko) | 2015-04-08 |
SG11201408530YA (en) | 2015-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015000683A (es) | Metodo para producir moleculas monomericas y multimericas y uso de las mismas. | |
AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
GB201008682D0 (en) | Epitope tag for affinity based applications | |
EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
NZ630848A (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
EA201591294A1 (ru) | Рекомбинантный микроорганизм для применения в способе с повышенным выходом продукта | |
MX2015000681A (es) | Metodo para producir receptores de fc (fcr) solubles como fusion de fc con region de fc de inmunoglobulina inerte y uso de las mismas. | |
CY1121970T1 (el) | Συσκευες και μεθοδοι για την ανακυκλωση χωρις τηξη μπαταριων μολυβδου/οξεος | |
MX2019008417A (es) | Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas. | |
EP3543333A3 (en) | Method for screening alpha-amylases | |
NZ705575A (en) | Recombinant clostridium botulinum neurotoxins | |
PH12015502614A1 (en) | Thrombin cleavable linker with xten and its uses thereof | |
MX2014012838A (es) | Composiciones para cultivo celular y metodos para la produccion de polipetidos. | |
JP2015514423A5 (es) | ||
MY181068A (en) | Recombinant microorganism for improved production of fine chemicals | |
PH12016501094A1 (en) | Recombinant microorganism for improved production of fine chemicals | |
NZ719881A (en) | Plant cytochrome p450 | |
BR112016012229A2 (pt) | métodos de produção de polipeptídeos | |
EA201400192A1 (ru) | Клетка, ферментирующая пентозы | |
NZ713602A (en) | Method for refining protein including self-cutting cassette and use thereof | |
MX2013010392A (es) | Proteinas de fusion npp1. | |
WO2012028523A3 (en) | Prokaryotic expression construct | |
IN2014DN06660A (es) | ||
WO2015015518A3 (en) | Process for production of insulin and insulin analogues | |
MY184387A (en) | Improved surface display of functional proteins in a broad range of gram negative bacteria |